News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NEW YORK, March 6, 2024 /PRNewswire/ — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that …
Indapta Therapeutics Granted FDA Fast Track Designation for Natural Killer Cell Therapy for Hematologic Malignancies
Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). The company’s universal, allogeneic NK …
Indapta Therapeutics treats first subjects in Phase I cancer therapy trial
Indapta Therapeutics has commenced the Phase I clinical trial of natural killer (NK) cell therapy IDP-023, treating the first patients with multiple myeloma and non-Hodgkin’s lymphoma. Read full article
Natural Killer Cell Therapy to Be Studied in Blood Cancers
A phase 1 trial recently kicked off evaluating the novel drug, IDP-023 for the treatment of patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma, according to a news …
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer …
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place
In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol visits/diagnostic testing. Studies suggest that the travel strain …
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the Group …
MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-101
MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient …
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today …
Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRC
David Sommerhalder, MD, medical oncologist, hematologist, Texas Oncology, director, Clinical Research, NEXT Oncology, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer (CRC). Read the full …